As of November 6, 2026, Revolution Medicines, Inc. is a publicly traded company (Nasdaq: RVMD); its largest reported holder is Dapice Joshua J., with 7.5% on Schedule 13G/A of February 9, 2026, then Fidelity (FMR) (7.2%) (Schedule 13G/A, February 9, 2026).
Is this your company?
About to sign with, pay or invest in Revolution Medicines, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Revolution Medicines, Inc. a real, registered company?
- Revolution Medicines, Inc. files with the SEC under CIK 1628171 (its SEC filings).
- Its shares are listed under the ticker RVMD on Nasdaq (also RVMDW) (SEC company record).
- Incorporated in Delaware; business address in Redwood City, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under REVOLUTION MEDICINES INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Steve Kelsey (Form 8-K filed 2026-06-22). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Revolution Medicines, Inc.'s owners and officers?
Revolution Medicines, Inc.: incorporated in Delaware; business address in Redwood City, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 7.2% |
| Schedule 13G, 2026-10-30 | Vanguard Capital Management | 5.13% |
| Schedule 13G, 2026-08-14 | Baker Bros. Advisors LP | 5.3% |
| Schedule 13G, 2026-08-13 | Janus Henderson Group LTD. | 5.1% |
| Schedule 13G/A, 2026-08-13 | Farallon Capital Management, L.L.C. | 6.4% |
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 5.7% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 4.9% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Baker Bros. Advisors LP | 4.9% |
| Schedule 13G/A, 2026-02-10 | Wellington Management Group LLP | 3.6% |
| Schedule 13G/A, 2026-02-09 | Dapice Joshua J. | 7.5% |
| Schedule 13G/A, 2025-11-14 | Janus Henderson Group PLC | 6.1% |
Questions about who owns Revolution Medicines, Inc.
Who owns Revolution Medicines, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Revolution Medicines, Inc.: Dapice Joshua J. (7.5%, Schedule 13G/A, filed 2026-02-09), Fmr LLC (7.2%, Schedule 13G/A, filed 2026-11-05), Farallon Capital Management, L.L.C. (6.4%, Schedule 13G/A, filed 2026-08-13), Blackrock, Inc. (5.7%, Schedule 13G, filed 2026-07-29) and Baker Bros. Advisors LP (5.3%, Schedule 13G, filed 2026-08-14); 2 more are listed above.
Who are the largest shareholders of Revolution Medicines, Inc.?
By the share each holder's latest filing reports, the largest holders of Revolution Medicines, Inc. on this page are Dapice Joshua J. (7.5%), Fmr LLC (7.2%) and Farallon Capital Management, L.L.C. (6.4%).
When did Dapice Joshua J. buy into Revolution Medicines, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Dapice Joshua J. on this page is the Schedule 13G/A, filed 2026-02-09, reporting 7.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Revolution Medicines, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Revolution Medicines, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Revolution Medicines, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-06-22 | Steve Kelsey | departed | 2027-01-04 |
Which insiders own Revolution Medicines, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 7,601,087 shares (3.5% of shares outstanding), held indirectly through a nextech crossover i scsp (Form 4, 2024-12-09).
- , a director: 2,340,075 shares (1.1% of shares outstanding) (Form 4, 2026-06-23).
- , a director: 314,766 shares (0.15% of shares outstanding), 253,342 held directly and 61,424 indirectly (Form 4, 2026-09-18).
- Kelsey Stephen Michael: 286,307 shares (0.13% of shares outstanding) (Form 4, 2026-09-18).
- , the chief operating officer: 149,680 shares (0.07% of shares outstanding) (Form 4, 2026-09-18).
Shares outstanding: 216,292,323 as of 2026-10-30, from the company's latest SEC cover page.
How much has Revolution Medicines, Inc. raised?
No fundraising or offering filing from Revolution Medicines, Inc. is on file with us.
Keep reading
More on Revolution Medicines, Inc. and the records around it.
Revolution Medicines, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/revolution-medicines